BackViking Therapeutics Overview

Viking Therapeutics Long Term Debt

Latest long-term debt for 0VQA.L: $250M.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$254.67M
↑ 79984.91% YoYΔ $254.35M vs prior year quarter

Peer trimmed avg / median

Loading

Viking Therapeutics Long Term Debt History

Loading

Viking Therapeutics vs. peers: Long Term Debt Comparison

Loading

Viking Therapeutics Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Viking Therapeutics (0VQA.L) FAQ

Viking Therapeutics (0VQA.L) currently reports a long-term debt of $250M as of September 2026. That compares with $320K in the prior-year period — up 79984.9% year over year. Use the charts on this page to explore Viking Therapeutics's long-term debt history and peer comparisons.

Viking Therapeutics's long-term debt increased from $320K to $250M — a 79984.9% year-over-year increase (period ending September 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Viking Therapeutics reported $250M in long-term debt as of September 2026. That compares with $320K in the prior-year period — up 79984.9% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $250M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Viking Therapeutics, and consider following 0VQA.L for alerts when major investors trade the stock.

Viking Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $250M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing 0VQA.L with unrelated industries.